<DOC>
	<DOCNO>NCT00491946</DOCNO>
	<brief_summary>To obtain preliminary characterization plasma PK metabolites actinomycin-D child cancer .</brief_summary>
	<brief_title>A Pharmacokinetic Study Actinomycin-D Vincristine Children With Cancer</brief_title>
	<detailed_description>There fundamental lack knowledge regard optimal dose anti-cancer agent young child cancer , resultant increase risk morbidity , mortality inferior outcome . Of anti-cancer agent use frequently infant young child , drug least amount knowledge actinomycin-D. Actinomycin-D , use treatment several childhood cancer since 1960s . Despite longstanding widespread use pediatric oncology , virtually pharmacokinetic information safe appropriate age-based pediatric dosing derive . Actinomycin-D integral component rhabdomyosarcoma Wilms tumor therapy , pediatric oncologist continue administer durg despite gap knowledge .</detailed_description>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>6 month 18 year Due receive actinomycinD component cancer treatment Central venous catheter ( e.g . Porta Cath , Broviac ) Informed consent parent legal guardian patient assent appropriate Serious illness primary diagnosis cancer Weight &lt; 5 kilogram Previous participation CHP810</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Actinomycin</keyword>
	<keyword>Vincristine</keyword>
</DOC>